By vgreene, 10 October, 2020 Study considerations not peer reviewed non comparative plasma from different donors days from dx to transfusion heterogeneous potential clustering web based case reporting
By vgreene, 10 October, 2020 Adjusted 7-day mortality rate 8.7% (transfused w/in 3 days of dx) and 11.9% (transfused 4 or more days after dx); similar findings w/ 30-day mortality rate; mortality rate inversely related to Ab levels in transfused plasma
By vgreene, 10 October, 2020 Multicenter open-label Expanded Access Program; 35,322 hospitalized pts (60% pts over 60y, 60% male, 52.3% ICU pts, 27.5% mech vent pts) w/ severe or life-threatening COVID-19 received at least 1 unit (150-250 mL) ABO-compatible COVID-19 convalescent pl
By vgreene, 10 October, 2020 Effect of Convalescent Plasma on Mortality Among Hospitalized Patients With COVID 19 Initial Three Month Experience Joyner et al
By vgreene, 10 October, 2020 <a href=https://jamanetwork.com/journals/jama/article-abstract/2766943><b><u>Access <i>JAMA</i> abstract</u></b></a>
By vgreene, 10 October, 2020 <b>Study considerations:</b> randomized, but open label; early termination due to epidemic containment; small sample size, possibly underpowered; median time 30 days btwn sx onset and randomization; SOC not protocolized, study center variability; limited
By vgreene, 10 October, 2020 No significant difference in time to clinical improvement w/in 28 days overall (convalescent plasma 51.9%, control 43.1%); in pts w/ severe dz, time to clinical improvement rate higher w/ convalescent plasma (91.3%) vs control (68.2%); no significant di
By vgreene, 10 October, 2020 Donors recovered from COVID-19, discharged from hospital >14 days, S-protein-specific Ab titers >1:640
By vgreene, 10 October, 2020 Multicenter, open-label, randomized study; 103 hospitalized pts (median age 70y) w/ confirmed severe or life-threatening COVID-19, randomized 1:1 by dz severity to receive convalescent plasma 200 mL (n=52) or SOC alone (n=51)
By vgreene, 10 October, 2020 Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life threatening COVID 19 A Randomized Clinical Trial
